Pfizer: Paxlovid drug to treat COVID-19 does not prevent infection among family members

US pharmaceutical company Pfizer on April 29 announced a large test showing that oral pills Paxlovid The COVID-19 treatment developed by this company is not effective at preventing infection in people living with the patient.

According to Pfizer, the trial was conducted with 3,000 adults, living in the same household as someone who has symptoms or recently tested positive for the SARS-CoV-2 virus. These people took Paxlovid for 5 or 10 days or took a placebo. The results showed that those who took the drug for 5 days had a 32% lower risk of infection than the placebo group. This number increases to 37% for those who take Paxlovid for 10 days. However, this result is not statistically significant and may be due to randomness.

Pfizer said the safety data in the trial were consistent with previous studies, which showed that the Paxlovid pill was nearly 90 percent effective in preventing COVID-19 hospitalizations and deaths. if the user takes it for 5 days immediately after symptom onset.

Pfizer CEO Albert Bourla said that while disappointing about the drug’s effectiveness in preventing infection, the results of this study do not affect the efficacy and safety data that the company has tracked in the trial. prior experience in the treatment of COVID-19 patients.

Paxlovid has now been approved or authorized for emergency use in more than 60 countries around the world to treat high-risk COVID-19 patients. Pfizer forecasts that its Paxlovid drug sales this year could reach $ 24 billion.

* Invite readers to watch programs broadcast by Vietnam Television on TV Online and VTVGo!